Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma

✍ Scribed by Erika Resetkova; Ana M. Gonzalez-Angulo; Nour Sneige; Timothy J. Mcdonnell; Aman U. Buzdar; Shu Wan Kau; Yuko Yamamura; James M. Reuben; Gabriel N. Hortobagyi; Massimo Cristofanilli

• Book ID: 102111197
• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 159 KB
• Volume: 101
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.20465

✦ Synopsis

Abstract

BACKGROUND

Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC.

METHODS

Immunohistochemical assays for P53, MDM‐2, and MUC‐1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC.

RESULTS

After a median follow‐up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC‐1 had a significantly shorter median TTP and median OS compared with other patients.

CONCLUSIONS

Expression of P53 and MUC‐1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients. Cancer 2004. © 2004 American Cancer Society.